Q1 2019 Earnings Forecast for GENFIT S A/ADR (NASDAQ:GNFT) Issued By B. Riley

GENFIT S A/ADR (NASDAQ:GNFT) – Stock analysts at B. Riley cut their Q1 2019 EPS estimates for GENFIT S A/ADR in a research note issued to investors on Wednesday, June 12th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0.78) per share for the quarter, down from their prior forecast of ($0.73). B. Riley also issued estimates for GENFIT S A/ADR’s Q2 2019 earnings at ($0.89) EPS, Q3 2019 earnings at ($0.70) EPS, Q4 2019 earnings at ($0.98) EPS, FY2019 earnings at ($3.37) EPS, FY2020 earnings at ($3.90) EPS, FY2021 earnings at ($3.36) EPS, FY2022 earnings at $0.07 EPS and FY2023 earnings at $0.46 EPS.

Several other analysts have also commented on GNFT. Barclays started coverage on shares of GENFIT S A/ADR in a report on Monday, April 22nd. They issued an “overweight” rating and a $55.00 price objective for the company. HC Wainwright lowered their price objective on shares of GENFIT S A/ADR to $72.00 and set a “buy” rating for the company in a report on Monday, April 22nd. Leerink Swann started coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They issued an “outperform” rating and a $25.47 price objective for the company. Svb Leerink started coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They issued an “outperform” rating and a $58.00 price objective for the company. Finally, Roth Capital reiterated a “buy” rating on shares of GENFIT S A/ADR in a report on Tuesday, April 23rd. Five investment analysts have rated the stock with a buy rating, GENFIT S A/ADR has an average rating of “Buy” and an average target price of $52.62.



Shares of GNFT opened at $20.58 on Friday. GENFIT S A/ADR has a one year low of $20.12 and a one year high of $26.25.

Several hedge funds have recently added to or reduced their stakes in GNFT. Morgan Stanley purchased a new position in shares of GENFIT S A/ADR during the first quarter valued at approximately $206,000. BlueCrest Capital Management Ltd purchased a new position in shares of GENFIT S A/ADR during the first quarter valued at approximately $240,000. New York State Common Retirement Fund purchased a new position in shares of GENFIT S A/ADR during the first quarter valued at approximately $267,000. One68 Global Capital LLC purchased a new position in shares of GENFIT S A/ADR during the first quarter valued at approximately $270,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of GENFIT S A/ADR during the first quarter valued at approximately $449,000. Hedge funds and other institutional investors own 15.31% of the company’s stock.

About GENFIT S A/ADR

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Further Reading: How Important is Technical Analysis of Stocks

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.